Slide 1: Q2 2018 Revenues Conference Call
me cegedim Q2 2018 Revenues Conference Call July 26, 2018
Slide 2: Caution Concerning Forward-Looking Statements
Caution Concerning Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that
Slide 3: IFRS Rules
IFRS Rules IFRS 5 : Owing to the disposal of the Group’s Cegelease and Eurofarmat businesses, announced in 2017 and completed on February 28, 2018, the consolidated 2017 and 2018 financial statements are presented according to IFRS 5, “Non-current assets held for sale and discontinued”. See the anne
Slide 4: Q2 and HY 2018 Revenue
Q2 and HY 2018 Revenue Revenue Revenue growth continues 4
Slide 5: Q2 2018 Revenue Growth
Q2 2018 Revenue Growth 5 © cegedim 2018
Slide 6: HY 2018 Revenue Growth
HY 2018 Revenue Growth © cegedim 2018
Slide 7: BPO Revenue
eee §=PBPO Revenue Revenue Q2 - 2018 HALF-YEAR REVENUE GROWTH a~s — C1 7 9m ($317) 3 €16.1m Chart legend €12.3m BPO INSURANCE b Ib U i ) RC PULSE 631D —-€7.8m ~ €5.9m €4.5m © cegedim 2018
Slide 8: Headcount
eee §=Headcount “Revenue Q2 - 2018 — —_ — \ \ . ; — (18.6% J. (44.8% J (41.8% J 4,036 4,230 4,307 : i | : JUN. 2015 DEC. 2016 Dec. 2017 JUN. 2018 © cegedim 2018
Slide 9: Health Insurance, HR & e-services Division
Health Insurance, HR & e-services Division The activities that made the biggest contributions to growth over the first half were Cegedim SRH (HR management solutions), Cegedim e-business (data flow and process digitalization), sales statistics for pharmaceutical products, and third-party payment sys
Slide 10: Healthcare Professionals Division
Healthcare Professionals Division As expected, over the first half, the division was hampered by its doctor computerization businesses in the US, the UK, and Spain as they prepare to launch new products whose impact won’t be felt until 2019. The pharmacy computerization business in France was hurt b
Slide 11: FY 2018 Cegedim Outlook
FY 2018 Cegedim Outlook Outlook as of July 26, 2018 11
Slide 12: Outlook: Cautiously Optimistic for 2018
Outlook: Cautiously Optimistic for 2018 • Building on its successful actions in 2017, Cegedim continues to pursue a strategy of focusing on ORGANIC GROWTH fueled by a policy of SUSTAINED INNOVATION • The Group expects for 2018: • Moderate organic revenue growth and EBITDA margin improvement • Becaus
Slide 13: Potential Impact of Brexit
Potential Impact of Brexit • Cegedim operates in the UK in local currency, as it does in all the countries where it operates • No major European health program is at work in the UK Thus, the impact on the consolidated Group EBIT margin should be marginal 10.9% UK revenue as a share of 2017 consoli
Slide 14: HY 2018 Revenue Annexes
HY 2018 Revenue Annexes as of July 26, 2018 14
Slide 15: Application of IFRS 5
Application of IFRS 5 On December 14, 2017, Cegedim announced that it had signed a contract for the definitive sale of its Cegelease and Eurofarmat businesses. The deal was finalized on February 28, 2018. As a result, the consolidated 2017 and 2018 financial statements are presented according to IFR
Slide 16: Shareholder Structure as of June 30, 2018
Shareholder Structure as of June 30, 2018 16
Slide 17: 2018 Financial Calendar
2018 Financial Calendar 17 © cegedim 2018
Slide 18: Follow us
Follow us WEB SITE www.cegedim.com/finance IR APP WEBCAST CEGEDIM IR SOCIAL NETWORK 18 @cegedimgroup © cegedim 2018
Slide 19: Jan Eryk Umiastowski
Jan Eryk Umiastowski Chief Investment Officer – Head of Investor Relations janeryk.umiastowski@cegedim.com Tel: 00 33 1 49 09 33 36 – Mob: 00 33 6 73 25 96 34 Design: Group Communications Department